ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 57 for:    Recruiting, Not yet recruiting, Available Studies | "Ischemic Attack, Transient"

Biomarkers for the Diagnosis of Transient Ischemic Attack (MAESTRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02799511
Recruitment Status : Recruiting
First Posted : June 15, 2016
Last Update Posted : August 17, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Caen

Brief Summary:

A transient ischemic attack (TIA) should be considered an emergency prevention opportunity in order to avoid recurrence as cerebral infarction (CI) serious (fatal or disabling). Indeed, about 20% of patients who have IC had in previous days or weeks, a TIA, which can be defined as a brief episode of cerebral dysfunction (or eye) do not result in permanent brain damage and thus no sequelae. Moreover, about 20% of ischemic events observed in practice are AIT. Despite the progress achieved in the treatment in the acute phase of an IC, prevention remains the most effective way to fight against this disease. This prevention can be put in place before the occurrence of a first IC, or after a first IC, especially when minor as a TIA.

However, the diagnosis of TIA remains particularly difficult and it is necessary now to identify new tools for the diagnosis of transient ischemic attack. Our study focused on the identification of one or more molecules (called biological markers or biomarkers) present in the bloodstream of patients, which will serve to facilitate the differential diagnosis of patients with TIA.


Condition or disease Intervention/treatment Phase
Cerebrovascular Disorders Ischemic Attack, Transient Biological: protein expression Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Biomarkers for the Diagnosis of Transient Ischemic Attack
Study Start Date : March 2015
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
protein expression Biological: protein expression
Differential protein expression between the period of acute cerebral ischemia and the control period




Primary Outcome Measures :
  1. change in proteomic analysis from MPs or from plasma. [ Time Frame: baseline and 72h after TAI and 90 days after TAI ]
    Identify one or more markers of transient ischemic attack by a proteomic analysis from MPs or from plasma.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TIA lasting 18h
  • NIHSS < 0
  • MRI diffusion hypersignal less than 5 ml
  • follow up during 3 month
  • written informed consent prior to any study procedures

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • major comorbidity (cancer, chronic infection)
  • recent trauma (less than 30 days) (cranial or extracranial)
  • Surgical or endovascular recent surgery(within 30 days).
  • Any old brain injury
  • Any acute pathology likely to induce inflammation, hemostasis disorders ...
  • Contraindications to MRI: Patients with a pacemaker, an implanted material activated by an electrical, magnetic or mechanical carriers hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants, claustrophobic ...
  • Patient under guardianship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02799511


Contacts
Contact: COGEZ Julien, MD +33 2 31 06 46 24 cogez-j@chu-caen.fr

Locations
France
Caen University Hospital Recruiting
Caen, France, 14033
Contact: Cogez Julien, MD         
Sponsors and Collaborators
University Hospital, Caen

Responsible Party: University Hospital, Caen
ClinicalTrials.gov Identifier: NCT02799511     History of Changes
Other Study ID Numbers: 2014-A00346-41
First Posted: June 15, 2016    Key Record Dates
Last Update Posted: August 17, 2018
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by University Hospital, Caen:
biological markers

Additional relevant MeSH terms:
Ischemia
Ischemic Attack, Transient
Cerebrovascular Disorders
Pathologic Processes
Brain Ischemia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases